Skip to main content
SpringerLink
Log in

AG 3340

  • Section 1: Matrix Metalloprotease Inhibitor
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Collier MA, Yuen GJ, Bansal SK, et al. A phase I study of the matrix metalloproteinase inhibitor AG3340 given in single doses to healthy volunteers. 88th Annual Meeting of the American Association for Cancer Research; 1997 Apr 12–16; San Diego. Philadelphia: American Association for Cancer Research, 1997: 221

    Google Scholar 

  2. Agouron Pharmaceuticals. Agouron Pharmaceuticals/phase I data presented on Agouron’s oral anti-angiogenesis drug AG3340. Media Release: [2 pages], 1998 Jun 22

    Google Scholar 

  3. Hande K, Wilding G, Ripple G, et al. A phase I study of AG3340, a matrix metalloprotease inhibitor, in patients having advanced cancer. Ann Oncol 1998; 9 Suppl. 2: 74

    Google Scholar 

  4. Wu EY, Ternavan MJ, Kosa M, et al. Metabolism and pharmacokinetics studies with the matrix metalloproteinase inhibitor, AG3340. Pharm Res 1996 Sep; 13 Suppl.: 507

    Google Scholar 

  5. Shalinsky D, Brekken J, Zou H, et al. AG3340, a novel MMP inhibitor, has a superior therapeutic index to carboplatin in nude mice bearing chemoresistant human MV522 lung cancer tumors. Ann Oncol 1998; 9 Suppl. 2: 73

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

AG 3340. Drugs R&D 1, 137–138 (1999). https://doi.org/10.2165/00126839-199901020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199901020-00004

Keywords

Search

Navigation